Aardvark Therapeutics appoints Abivax Chief Strategy Officer David Zhang to board
AARD•Aardvark Therapeutics appointed David Zhang, Abivax’s chief strategy officer, as an independent director, effective Oct. 7, 2026.
1. Board appointment
Zhang oversees biometrics, regulatory affairs, quality assurance and HEOR at Abivax. He previously led biometrics and data management at Alumis, served as interim CIO and supported the company through its IPO.
2. Previous roles
Zhang held biometrics leadership roles at MyoKardia, working on CAMZYOS clinical strategy and NDA work, and earlier roles at Genentech and Roche.
